{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:30:41Z","timestamp":1789140641933,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.oret.2025.05.033","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T19:39:51Z","timestamp":1748979591000},"page":"1167-1174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Outcomes of Patients with Proliferative Diabetic Retinopathy Treated with Anti-VEGF Therapy and\/or Panretinal Photocoagulation in the United States Who Were Lost to Follow-up"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5198-1353","authenticated-orcid":false,"given":"Rahul N.","family":"Khurana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay C.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Lum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2025.05.033_bib1","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","article-title":"Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis","volume":"128","author":"Teo","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.05.033_bib2","doi-asserted-by":"crossref","first-page":"e1221","DOI":"10.1016\/S2214-109X(17)30393-5","article-title":"Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis","volume":"5","author":"Flaxman","year":"2017","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.oret.2025.05.033_bib3","first-page":"383","article-title":"The Diabetic Retinopathy Study Research Group","volume":"81","year":"1976","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2025.05.033_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/eme05050","article-title":"Intravitreal aflibercept compared with panretinal photocoagulation for proliferative diabetic retinopathy: the CLARITY non-inferiority RCT","volume":"5","author":"Sivaprasad","year":"2018","journal-title":"Efficacy Mech Eval"},{"key":"10.1016\/j.oret.2025.05.033_bib5","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jcjo.2021.01.017","article-title":"Intravitreal anti-vascular endothelial growth factor versus panretinal LASER photocoagulation for proliferative diabetic retinopathy: a systematic review and meta-analysis","volume":"56","author":"Yates","year":"2021","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.oret.2025.05.033_bib6","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1001\/jama.2015.15217","article-title":"Writing Committee for the Diabetic Retinopathy Clinical Research Network. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial","volume":"314","author":"Gross","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.oret.2025.05.033_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2021.100037","article-title":"Temporal trends in the treatment of proliferative diabetic retinopathy: an AAO IRIS\u00ae Registry analysis","volume":"1","author":"Gong","year":"2021","journal-title":"Ophthalmol Sci"},{"key":"10.1016\/j.oret.2025.05.033_bib8","doi-asserted-by":"crossref","first-page":"e567","DOI":"10.1111\/j.1755-3768.2011.02184.x","article-title":"Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy","volume":"89","author":"Filho","year":"2011","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.oret.2025.05.033_bib9","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ajo.2020.03.011","article-title":"Loss to follow-up among patients with proliferative diabetic retinopathy in clinical practice","volume":"215","author":"Suresh","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2025.05.033_bib10","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ajo.2020.03.023","article-title":"Predictors of lost to follow-up in patients being treated for proliferative diabetic retinopathy","volume":"216","author":"Green","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2025.05.033_bib11","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ophtha.2018.02.034","article-title":"Loss to follow-up in patients with proliferative diabetic retinopathy after panretinal photocoagulation or intravitreal anti-VEGF injections","volume":"125","author":"Obeid","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.05.033_bib12","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.50942","article-title":"Loss to follow-up in patients with proliferative diabetic retinopathy or diabetic macular edema","volume":"7","author":"Huang","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.oret.2025.05.033_bib13","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.oret.2024.04.016","article-title":"Loss to follow up in patients with proliferative diabetic retinopathy treated with anti-VEGF therapy and\/or panretinal photocoagulation in the United States","volume":"8","author":"Khurana","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2025.05.033_bib14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/IAE.0000000000003911","article-title":"Characteristics of participants in diabetic retinopathy clinical research clinical trials who were lost to follow-up","volume":"44","author":"Bowe","year":"2024","journal-title":"Retina"},{"key":"10.1016\/j.oret.2025.05.033_bib15","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ophtha.2018.07.027","article-title":"Outcomes of eyes lost to follow-up with proliferative diabetic retinopathy that received panretinal photocoagulation versus intravitreal anti\u2013vascular endothelial growth factor","volume":"126","author":"Obeid","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.05.033_bib16","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.ophtha.2017.12.001","article-title":"The 2016 American Academy of Ophthalmology IRIS\u00ae Registry (Intelligent Research in Sight) database: characteristics and methods","volume":"125","author":"Chiang","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.05.033_bib17","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ophtha.2023.02.021","article-title":"Loss to follow-up in patients with neovascular age-related macular degeneration treated with anti-VEGF therapy in the United States in the IRIS\u00ae Registry","volume":"130","author":"Khurana","year":"2023","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.05.033_bib18","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1001\/jama.280.19.1690","article-title":"What\u2019s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes","volume":"280","author":"Zhang","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.oret.2025.05.033_bib19","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1001\/jamaophthalmol.2022.3929","article-title":"Representation of race and ethnicity in randomized clinical trials of diabetic macular edema and retinal vein occlusion compared to 2010 US census data","volume":"140","author":"Kaakour","year":"2022","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2025.05.033_bib20","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.oret.2023.07.015","article-title":"Racial and ethnic distribution in diabetic macular edema clinical trials in the United States (2002-2021)","volume":"7","author":"Yu","year":"2023","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2025.05.033_bib21","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","article-title":"Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders","volume":"331","author":"Aiello","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.oret.2025.05.033_bib22","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00006982-200603000-00004","article-title":"Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage","volume":"26","author":"Spaide","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.oret.2025.05.033_bib23","doi-asserted-by":"crossref","first-page":"1695.e1","DOI":"10.1016\/j.ophtha.2006.05.064","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.05.033_bib24","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jamaophthalmol.2021.4103","article-title":"Lapses in care among patients assigned to ranibizumab for proliferative diabetic retinopathy: a post hoc analysis of a randomized clinical trial","volume":"139","author":"Maguire","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2025.05.033_bib25","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/aos.14644","article-title":"Global burden and gender disparity of vision loss associated with diabetes retinopathy","volume":"99","author":"Xu","year":"2021","journal-title":"Acta Ophthalmol"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653025002702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653025002702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T07:39:23Z","timestamp":1764747563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653025002702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2468653025002702"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2025.05.033","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of Patients with Proliferative Diabetic Retinopathy Treated with Anti-VEGF Therapy and\/or Panretinal Photocoagulation in the United States Who Were Lost to Follow-up","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2025.05.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}